Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Actavis Inc. (a subsidiary of Teva) developed a generic topical gel formulation containing clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) for the treatment of acne vulgaris. This product is a generic equivalent of the brand-name drug Onexton. Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically targeting Cutibacterium acnes (formerly Propionibacterium acnes). Benzoyl peroxide is an oxidizing agent with bactericidal activity against C. acnes and also possesses keratolytic and anti-inflammatory properties. The combination therapy addresses multiple pathogenic factors of acne, including bacterial proliferation, follicular hyperkeratosis, and inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clindamycin + benzoyl peroxide (Allergan).